MedTrace Logo

A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

NCT07564401 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-05-22

No results posted yet for this study

Summary

This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and preliminary efficacy of DJI136.

Conditions

  • Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Interventions

DRUG

DJI136

DLL3 targeted CAR-T therapy administered by intravenous (i.v.) infusion.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-14
Primary Completion
2031-03-03
Completion
2031-03-03
FDA Drug
Yes

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07564401 on ClinicalTrials.gov